Dr. Bunn on the MYSTIC Trial for Lung Cancer
Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).
Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non—small cell lung cancer (NSCLC).
Further details are needed from this trial in order to come to a conclusion regarding its results, states Bunn.
This study did not meet its primary endpoint of progression-free survival, explains Bunn. The study investigated chemotherapy versus durvaluamab (Imfinzi) and tremilumumab versus durvalumab alone. There were a number of different subsets that need to be analyzed further.
